You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006–2014)
|
|---|---|
| Published in |
Vaccine, February 2015
|
| DOI | 10.1016/j.vaccine.2015.01.081 |
| Pubmed ID | |
| Authors |
David Bin-Chia Wu, Nathorn Chaiyakunapruk, Huey-Yi Chong, Philippe Beutels |
| Abstract |
Seven-valent pneumococcal conjugate vaccines (PCV7) have been used in children for more than a decade. Given the observed increase in disease caused by pneumococcal serotypes not covered by PCV7, an increasing number of countries are switching from 7-valent to 10- and 13-valent PCVs ("PCV10" and "PCV13"). Economic evaluations are important tools to inform decisions and price negotiations to make such a switch. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Unknown | 97 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 23% |
| Researcher | 18 | 18% |
| Student > Ph. D. Student | 11 | 11% |
| Student > Bachelor | 9 | 9% |
| Student > Postgraduate | 5 | 5% |
| Other | 13 | 13% |
| Unknown | 19 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 38% |
| Immunology and Microbiology | 6 | 6% |
| Economics, Econometrics and Finance | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Agricultural and Biological Sciences | 5 | 5% |
| Other | 13 | 13% |
| Unknown | 26 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2017.
All research outputs
#2,614,970
of 25,374,917 outputs
Outputs from Vaccine
#2,193
of 16,509 outputs
Outputs of similar age
#36,686
of 367,188 outputs
Outputs of similar age from Vaccine
#25
of 170 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,509 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.7. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,188 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 170 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.